To evaluate whether patients with late complications of pacemakers or implantable cardioverter-defibrillators have hypersensitivity reactions to some of the materials used in generators or in electrodes, or to environmental metal burden. The cohort consisted of 20 men and 4 women (mean age: 62.3 ± 17.2 years) who had a history of late complications of implanted devices. The control group involved 25 men and 8 women (mean age: 64.6 ± 14.0 years) who had comparable devices, but no history of late complications. Lymphocyte transformation test was used to evaluate hypersensitivity to eight metal pollutants (antimony, manganese, mercury, molybdenum, nickel, platinum, tin, and titanium) selected by results of questionnaires on environmental burden, and by material analysis of generators and electrode surfaces. Exposures to metal pollutants were approximately the same in patients and in controls. Titanium alloy used in generators contained at least 99.32% of titanium and trace levels of other metals; higher levels of tin and platinum were detected in electrode surfaces. Hypersensitivity reactions to mercury and tin were significantly more frequent in patients than in controls (patients and controls: mercury: 68.2 and 31.1%, respectively; P = 0.022; tin: 25.0 and 3.2%, respectively; P = 0.035). In contrast, hypersensitivity to manganese was significantly more frequent in controls than in patients (patients and controls: 13.6 and 50.0%, respectively; P = 0.008). Our findings suggest a possible relation between hypersensitivity to metals used in implantable devices or to environmental metal burden and the occurrence of their late complications.

Background. Acquired calcified aortic valve stenosis is the most common valve disease in adulthood. In the etiopathogenesis of this complex pathology, the importance of inflammation is mentioned, in which non-infectious influences represented by the biological effects of metal pollutants may participate. The main goal of the study was to determine the concentration of 21 metals and trace elements—aluminium (Al), barium (Ba), cadmium (Cd), calcium (Ca), chrome (Cr), cobalt (Co), copper (Cu), gold (Au), lead (Pb), magnesium (Mg), mercury (Hg), molybdenum (Mo), nickel (Ni), phosphorus (P), selenium (Se), strontium (Sr), sulfur (S), tin (Sn), titanium (Ti), vanadium (V) and zinc (Zn)—in the tissue of calcified aortic valves and to compare them with the concentrations of the same elements in the tissue of healthy aortic valves in the control group. Material and methods. The study group consisted of 49 patients (25 men, mean age: 74) with acquired, severe, calcified aortic valve stenosis with indicated heart surgery. The control group included 34 deceased (20 men, median age: 53) with no evidence of heart disease. Calcified valves were explanted during cardiac surgery and deep frozen. Similarly, the valves of the control group were removed. All valves were lyophilized and analyzed by inductively coupled plasma mass spectrometry. The concentrations of selected elements were compared by means of standard statistical methods. Results. Calcified aortic valves contained significantly higher (p < 0.05) concentrations of Ba, Ca, Co, Cr, Mg, P, Pb, Se, Sn, Sr and Zn and—in contrast—lower concentrations of Cd, Cu, Mo, S and V than valves of the control group. Significant positive correlations of concentrations between the pairs Ca-P, Cu-S and Se-S and strong negative correlations between the elements Mg-Se, P-S and Ca-S were found in the affected valves. Conclusion. Aortic valve calcification is associated with increased tissue accumulation of the majority of the analyzed elements, including metal pollutants. Some exposure factors may increase their accumulation in the valve tissue. A relationship between exposure to environmental burden and the aortic valve calcification process cannot be ruled out. Advances in histochemical and imaging techniques allowing imaging of metal pollutants directly in valve tissue may represent an important future perspective.

Background: Long-term efficacy of catheter ablation for atrial fibrillation (AF) greatly declines with time.

Funding Acknowledgements: Type of funding sources: None. Background: Benefits of pulsed field ablation (PFA) compared to radiofrequency ablation (RFA) are not known in patients with longstanding persistent atrial fibrillation (LSPAF). Purpose: To present interim procedural and short-term clinical results of an ongoing prospective randomized comparison of PFA vs. RFA in patients with LSPAF. Methods: In 9/2021-10/2022, 125 patients underwent catheter ablation for LSPAF using PFA (n=64, 69±8 years, 11 F, continuous AF 32±20 months) vs. RFA (n=61, 68±8 years, 17 F, continuous AF 29±23 months). PFA included pulmonary vein isolation (PVI) and extra-PV left atrial (LA) ablation. RFA included stepwise PVI, electrogram-guided LA ablation, CS isolation, and electrogram-guided right atrial ablation. Intermediate endpoints were PVI, mitral isthmus, LA roof and CTI blocks); sinus rhythm (SR) restoration by ablation was the desired procedural endpoint. Follow-up included 7-day ECG monitoring every 3 months during the first year, and every 6 months afterwards. Results: In groups PFA vs. RFA, procedure and fluoroscopy times were 116±32 vs. 204±44 minutes, and 17±5 vs. 8±2 minutes, respectively (both p30 s) was achieved in 38 (79%) vs. 23 (46%) patients. Conclusion: Interim results of ongoing comparison suggest procedure time reduction and improved AF/AT free survival after PFA as compared to RFA in patients with LSPAF.

Funding Acknowledgements: Type of funding sources: None. Background: Pulsed field ablation (PFA) is a promising method to reduce procedure time and improve ablation safety and efficacy in all types of atrial fibrillation (AF). Purpose: To present ablation approach and medium-term outcomes of PFA in all AF types. Methods: Between 9/2021-10/2022, PFA using Farawave catheter was performed in 250 patients (63±11 years, 65 females). Patients with paroxysmal AF were basically scheduled for simple pulmonary vein isolation (PVI) (Farawave, ICE), patients with longstanding AF (LSPAF) underwent complex left atrial (LA) PFA (Farawave, CS 10-pole catheter, ICE); ablation extent varied in persistent AF. Results: Paroxysmal AF (n=131; 115 ablated in SR), persistent AF (n=39; 11 ablated in SR), and LSPAF (n=64) were ablated with procedure times 58±20, 105±28, and 116±32 minutes, respectively, and fluoroscopy times 9±5, 14±7, and 17±7 minutes, respectively. Additional 16 patients underwent PFA for atrial tachycardia (AT). Ongoing AF was terminated by PFA in 13/16 (81%), 16/28 (57%), and 23/64 (36%) patients with paroxysmal AF, persistent AF, and LSPAF, respectively. In groups of paroxysmal AF ablated in SR, paroxysmal AF ablated in AF, persistent AF ablated in SR, persistent AF, and LSPAF, simple PVI was performed in 100%, 50%, 73%, 11%, and 0 patients respectively; and freedom from AF/AT was present in 86/99 (87%), 11/14 (79%), 7/10 (70%), 11/12 (92%), and 40/52 (77%) patients, respectively, of total 187 patients with follow-up ≥3 months (≥6 months in 139 patients). In 8 patients with repeat ablation post-PFA for paroxysmal AF (n=4), persistent AF (n=2), LSPAF (n=2), extra-PV AF/AT sources dominated in all groups. Complications included one tamponade with pericardiocentesis, and prolonged ST elevation with negative coronary angiography. Conclusion: PFA using Farawave catheter was associated with reduced procedure times and favourable medium-term outcome for all AF types. Early experience specifically suggests improved outcome after extensive LA ablation for persistent AF/LSPAF.

Purpose: Single center retrospective analysis of complications of catheter ablation for paroxysmal atrial fibrillation (PAF).